

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Lead Optimization of *N*<sup>6</sup>-Cyclopentyl-3'-amido-3'-deoxyxylofuranosyladenines as Adenosine A<sub>1</sub> Receptor Antagonists

S. Van Calenbergh<sup>a</sup>; A. Link<sup>b</sup>; D. De Keukeleire<sup>a</sup>; P. Herdewijn<sup>a</sup>

<sup>a</sup> Laboratory for Medicinal Chemistry (FFW), University of Gent, Belgium <sup>b</sup> Institut für Pharmazie, Universität Hamburg, Germany

**To cite this Article** Van Calenbergh, S. , Link, A. , De Keukeleire, D. and Herdewijn, P.(1999) 'Lead Optimization of *N*<sup>6</sup>-Cyclopentyl-3'-amido-3'-deoxyxylofuranosyladenines as Adenosine A<sub>1</sub> Receptor Antagonists', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 735 – 736

**To link to this Article:** DOI: 10.1080/15257779908041558

**URL:** <http://dx.doi.org/10.1080/15257779908041558>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**LEAD OPTIMIZATION OF *N*<sup>6</sup>-CYCLOPENTYL-3'-AMIDO-3'-DEOXY-XYLOFURANOSYLADENINES AS ADENOSINE A<sub>1</sub> RECEPTOR ANTAGONISTS**

S. Van Calenbergh<sup>1</sup>, A. Link<sup>2</sup>, D. De Keukeleire<sup>1</sup> and P. Herdewijn<sup>1\*</sup>

<sup>1</sup>Laboratory for Medicinal Chemistry (FFW), University of Gent, Belgium,

<sup>2</sup>Institut für Pharmazie, Universität Hamburg, Germany,


**ABSTRACT** : Strategies toward the further lead optimization of *N*<sup>6</sup>-cyclopentyl-3'-amido-3'-deoxyxylofuranosyladenosines as adenosine A<sub>1</sub> receptor antagonists including the synthesis of the 5'-deoxy-analogues and a practical method for parallel amidation are presented.

The effects of numerous modifications of the adenosine scaffold on affinity and intrinsic activity towards adenosine A<sub>1</sub> receptors are well documented. Most modifications at the 2' and 3' positions of the sugar ring or inversion of chiral centers at these positions are found to abolish A<sub>1</sub> receptor binding.


Recently we demonstrated that substitution of the ribofuranosyl moiety of *N*<sup>6</sup>-cyclopentyladenosine (CPA) for a 3'-amido-3'-deoxyxylofuranosyl moiety results in potent and selective A<sub>1</sub> receptor antagonists.<sup>1</sup>

Here we describe our efforts towards further lead optimization. First we developed a route to prepare the 5'-deoxy analogue of the amine synthon of **1**. Such modification should avoid our new analogues to be susceptible to phosphorylation and incorporation into DNA. It was achieved in 4 steps from *N*<sup>6</sup>-cyclopentyl-5'-deoxyadenosine (see Scheme 1). Subsequently, we set up a solid-phase assisted synthesis designed for the acylation of the weakly nucleophilic 3'-amino group of 9-(3'-amino-3'-deoxyxylofuranosyl)-*N*<sup>6</sup>-cyclopentyladenine<sup>1</sup> (**1a**) and its 5'-deoxy analogue (**1b**). This was achieved by coupling the selected acids to the Kenner safety catch linker improved by Ellman et al. using standard amide bond forming procedures.<sup>2</sup> Cyanomethylation of

the linker resulted in highly reactive polymer bound acids that could easily be coupled with the aforementioned amines (see Scheme 2).



Scheme 1  $\triangle$ , Scheme 2  $\nabla$



Filtration of the beads and removal of the solvent afforded 3'-amido-3'-(5')-(di)deoxyxylofuranosyl CPA analogues (**2a,b**) in high yield ready for biological testing.

## REFERENCES

1. Van Calenbergh, S.; von Frijtag Drabbe Künzel, J. K.; Blaton, N. M.; Peeters, O. M.; Rozenski, J.; Van Aerschot, A.; De Bruyn, A.; De Keukeleire, D.; IJzerman, A. P.; Herdewijn, P. *J. Med. Chem.* **1997**, *40*, 3765-3772.
2. Backes, B. J.; Virgilio, A. A.; Ellman, J. A. *J. Am. Chem. Soc.* **1996**, *118*, 3055-3056.
3. Davidson, J.G.; Fiore, P.J. *Nucleosides & Nucleotides* **1991**, *10*, 1477-1483.